Category: Critical Care

February podcast and round up: St Emlyn’s

We made it! A double century of podcasts. In this month’s update Iain and Simon talk through myth busting in resuscitation, Rick Body’s airway expertise (with a side mention for high sensitivity troponin), a paper about resuscitative thoracotomy, ACPs

JC: The RePHILL trial. St Emlyn’s

This week we see the publication of the RePHILL trial. This is something we have been looking forward to for some time. A randomised controlled trial of the use of packed red cells, LyoPLAS and

Bezold Jarisch

What is the Bezold-Jarisch Reflex and why do I care?! St Emlyn’s

Bradycardia in the trauma patient can be a perilous sign. One might observe a typical course of events in which a bleeding trauma patient progresses through the compensatory mechanisms in response to shock. It is

JC: More on pulse oximetry and racial bias. St Emlyn’s

This week we are reviewing a paper on the accuracy of pulse oximetry in patients being assessed for ECMO. This is an interesting group as they represent and extremely unwell group of patients where small

JC: The BASICS trial. 0.9% saline vs balanced solution. Does it matter?

I’ll admit that my long term clinical practice has been to prefer balanced solutions (in my case Hartmans) over 0.9% saline in the management of the critically ill patient. It’s a topic we’ve blogged and

convalescent plasma

JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s

The latest results on the use of convalescent plasma in Covid-19 are now out from the RECOVERY trial as a pre-print. As you know we have already covered the trial quite extensively and thus far

tocilizumab

Tocilizumabulous? A special offer on IL-6 with Tocilizumab.

It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it. Maybe not the one intervention

Tocilizumab

Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s

Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic agent for patients with severe

Tocilizumaybe? Immune modulation in COVID-19 @StEmlyns

I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is COVID19. This follows a press

VTE and COVID-19: Would you like to know more?

That’s a leading question. Of course you would.  Who wouldn’t want to know more about a disease that has killed >1 million people to date, worldwide. Who wouldn’t want to know more about the thromboembolic risk associated

MMU banner 1